Stable Isotope Labelled Satralizumab Biosimilar – Anti-IL6R mAb – Research Grade

Reference: PX-TA1407-SIL-1MG
Size

Brand

Product type

Clonality

Expression system

Applications

Product nameStable Isotope Labelled Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade
SourceCAS 1535963-91-7
SpeciesHumanized
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
ApplicationsMS
Aliases /SynonymsSA-237
ReferencePX-TA1407-SIL
Related ProductsPX-P4046
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG2-kappa
ClonalityMonoclonal Antibody
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

Description of Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade

General information on Anti-IL6R[Homo sapiens] (Satralizumab) Monoclonal Antibody

Satralizumab is a humanized monoclonal antibody that targets human interleukin-6 (IL-6) receptors, similar to tocilizumab. Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD). Increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier are thought to be mediated by IL-6. Satralizumab is thought to block IL-6 receptors and, thereby, these inflammatory responses.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Isotope Labelled Satralizumab Biosimilar – Anti-IL6R mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products